Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Exclusion Criteria

• •Prior treatment for MCL with chemotherapy
• •Pregnant or breastfeeding women
• •Grade 2 or higher peripheral neuropathy
• •Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study enrollment
• •Significant cardiovascular disease
• •Any condition that might significantly impair drug absorption as determined by the investigator
• •Uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study drug
• •History of stroke or intracranial hemorrhage within 6 months of 1st dose of study drug
• •Concurrent participation in another clinical trial
• •Subject has received a moderate or strong CYP3A inhibitor or inducer within 1 week prior to treatment initiation.
• •Psychiatric illness or social situations that would limit compliance with study requirements
• •Subject has known positivity to HIV
• •Active infection with Hepatitis B or C virus as determined by a detectable viral load on PCR.
• •Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to\< 2 years.